ARO-APOC3, an Investigational RNAi Therapeutic, Silences APOC3 and Reduces TG to Near Normal Levels in Patients With SHTG: SHASTA-2 Study Results

Daniel Gaudet, MD, PhD
ECOGENE-21 and Dept of Medicine, Université de Montréal
on behalf of the SHASTA-2 Study Team
Financial Disclosures

**Presenter**

**D Gaudet** reports grants and/or honoraria from Alnylam, Amgen, Arrowhead, AstraZeneca, Boehringer-Ingelheim, CRISPR Therapeutics, Dalcor Pharma, Eli Lilly, Esperion, Ionis, Kowa, Novartis, Pfizer, Regeneron, Sanofi, Ultragenyx and Verve Therapeutics.

**Co-Authors**

**D Pall** reports grants and/or honoraria from (all paid to institution, not individual) Arrowhead Pharmaceuticals Inc., AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Kowa, Novartis, NovoNordisk, Pfizer.

**SJ Nicholls** reports grants and/or honoraria from Akcea, Amarin, Amgen, Anthera, Arrowhead Pharmaceuticals Inc, AstraZeneca, Boehringer Ingelheim, Cerenis, CSL Behring, Eli Lilly, Esperion, InfraReDx, LipoScience, The Medicines Company, Merck, New Amsterdam Pharma, Novartis, Omthera, Resverlogix, Roche, Sanofi-Regeneron, and Takeda.

**CM Ballantyne** reports grants and/or honoraria from Abbott Diagnostic, Akcea, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo.

**GF Watts** reports grants and/or honoraria from Amgen, Novartis, Arrowhead, Esperion, AstraZeneca, Pfizer, Novo Nordisk, Silence Therapeutics, CSL Seqirus, and Sanofi-Regeneron.

**RS Rosenson** reports grant/research support from (all paid to institution, not individual): Amgen, Arrowhead, Novartis, Eli Lilly, Regeneron; consulting fees from Amgen, Arrowhead, CRISPR Therapeutics, Eli Lilly, Lipigon, Novartis, Precision Biosciences, Regeneron, UltraGenyx, Verve; non-promotional speaking fee from Amgen and Kowa; other support from MediMergent, LLC (significant); and is an UpToDate, Inc. stock shareholder (significant).

**T Chang, K Modesto, S Melquist, R Fu, and J San Martin** are all current employees of Arrowhead Pharmaceuticals.
Goal Of SHTG Therapy Is To Reduce TGs Below Pancreatitis Risk

- Severe hypertriglyceridemia (SHTG) is characterized by circulating triglycerides (TG) > 500 mg/dL\textsuperscript{1-3}

- In the United States (US), there are ~2-4 million adults with SHTG\textsuperscript{4-5}

- The etiology of SHTG is multi-factorial\textsuperscript{4-6}
  - Risk factors can include genetic disorders, obesity, untreated or poorly controlled diabetes, and certain medications
  - Very severe forms include FCS and MCS
    - FCS, the ultra-rare form, is due to monogenic mutations and is prevalent in >500 cases in the US
    - MCS is far more frequent than FCS and is usually associated with multigenic mutations and aggravating factors

- SHTG significantly increases the risk of ASCVD and acute pancreatitis (AP), often with recurrent attacks requiring repeat hospital admissions and worsening outcomes\textsuperscript{1-3,6}

- Limited treatment options exist to reduce TGs below the threshold at which pancreatitis occurs\textsuperscript{1-3}

**Key Features Of Using RNAi As A Therapeutic Modality**

RNAi is a natural process that uses short fragments of RNA molecules to interfere with mRNA translation into associated proteins.

- **High Specificity:** Allowing to suppress the expression of a specific gene
- **Potent Activity:** Deep and consistent silencing of target genes
- **Safety:** Minimal off target adverse effects due to targeted delivery (GalNAc) and sequence specificity
- **Infrequent Dosing:** Long tissue PK/PD, on target effect

---

**ASGPR, asialoglycoprotein receptor; GalNAc, N-Acetylgalactosamine; mRNA, messenger ribonucleic acid; PD, pharmacodynamic; pH, potential of Hydrogen; PK, pharmacokinetic; RISC, RNA-induced silencing complex; RNA, ribonucleic acid; RNAi, ribonucleic acid interference; siRNA, small interfering ribonucleic acids**
Plozasiran (ARO-APOC3) is an investigational RNAi therapeutic targeting ApoC3, a key mediator of TG and atherogenic lipoproteins.

1. Van Zwol W et al. J Clin Med. 2019; 8:1085. Chylomicrons are large triglyceride-rich lipoproteins produced in enterocytes from dietary lipids. Remnant cholesterol is a very atherogenic lipoprotein composed primarily of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL). It represents the amount of cholesterol in remnant lipoproteins. APOC3, apolipoprotein C3; LPL, lipoprotein lipase; RNAi, ribonucleic acid interference; TG, triglycerides; TRL, triglyceride-rich lipoproteins; VLDL, very-low-density lipoprotein.
SHASTA-2: A Double-blind, Phase 2b Placebo-Controlled, Dose Ranging Study Of Plozasiran In Subjects With SHTG

Study Objectives: To evaluate safety and efficacy for lowering TG and atherogenic lipoproteins and severity/occurrences of AP in subjects with SHTG, and to explore optimal dosing

Study Population: SHTG history of TG ≥ 500 mg/dL and fasting TG of 500 – 4,000 mg/dL during screening period

Key Endpoints*: % change from baseline and over time in:
- Primary endpoint: TG
- Key LP parameters: APOC3, non-HDL-C, LDL-C, HDL-C, APOB, Remnant Cholesterol
- Safety

Data Analysis: Phase 2 study data evaluated when all subjects had reached Week 24 cutoff date of April 14, 2023.

All subjects were eligible to enroll in the Open Label Extension (OLE) at the end of the study.

*All samples taken after ≥ 10 hour fast.

APOB, apolipoprotein B; APOC3, apolipoprotein C3; EOS, end of study; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; LP, lipoproteins; OLE, open label extension; SHTG, severe hypertriglyceridemia; TG, triglycerides.
## Baseline Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Pooled Placebo (N=60)</th>
<th>10 mg (N=54)</th>
<th>25 mg (N=55)</th>
<th>50 mg (N=57)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean (SD) age, years</strong></td>
<td>56.2 (11.0)</td>
<td>53.0 (9.6)</td>
<td>56.0 (10.6)</td>
<td>54.3 (11.0)</td>
</tr>
<tr>
<td><strong>Female, n (%)</strong></td>
<td>14 (23.3)</td>
<td>8 (14.8)</td>
<td>12 (21.8)</td>
<td>16 (28.1)</td>
</tr>
<tr>
<td><strong>White, n (%)</strong></td>
<td>55 (91.7)</td>
<td>47 (87.0)</td>
<td>48 (87.3)</td>
<td>53 (93.0)</td>
</tr>
<tr>
<td><strong>Mean (SD) BMI, kg/m²</strong></td>
<td>30.6 (3.8)</td>
<td>32.5 (4.9)</td>
<td>31.8 (5.1)</td>
<td>31.5 (5.3)</td>
</tr>
<tr>
<td><strong>Mean (SD) APOC3,a mg/dL</strong></td>
<td>30.6 (15.9)</td>
<td>33.4 (15.4)</td>
<td>34.5 (16.8)</td>
<td>31.6 (16.1)</td>
</tr>
<tr>
<td><strong>Median (Q1, Q3) triglyceride, mg/dL</strong></td>
<td>678.6 (539.6, 929.1)</td>
<td>696.0 (558.8, 1087.6)</td>
<td>597.7 (517.3, 982.1)</td>
<td>663.1 (530.8, 1028.3)</td>
</tr>
<tr>
<td><strong>Mean (SD) non-HDL-C, mg/dL</strong></td>
<td>184.8 (78.7)</td>
<td>208.8 (73.6)</td>
<td>206.3 (91.3)</td>
<td>195.7 (87.6)</td>
</tr>
<tr>
<td><strong>Mean (SD) ApoB, mg/dL</strong></td>
<td>94.91 (28.6)</td>
<td>103.10 (44.4)</td>
<td>103.44 (31.8)</td>
<td>109.80 (54.5)</td>
</tr>
<tr>
<td><strong>Mean (SD) remnant cholesterol,b mg/dL</strong></td>
<td>115.4 (82.2)</td>
<td>134.1 (87.9)</td>
<td>132.1 (98.3)</td>
<td>123.8 (91.5)</td>
</tr>
<tr>
<td><strong>Median (Q1, Q3) LDL-C, UC, mg/dL</strong></td>
<td>62.0 (42.0, 92.0)</td>
<td>65.0 (46.0, 96.0)</td>
<td>71.0 (44.0, 97.0)</td>
<td>65.0 (41.0, 96.0)</td>
</tr>
<tr>
<td><strong>Mean (SD) HDL-C, mg/dL</strong></td>
<td>29.7 (11.6)</td>
<td>28.3 (8.8)</td>
<td>29.5 (11.2)</td>
<td>30.5 (12.6)</td>
</tr>
</tbody>
</table>
Plozasiran Demonstrates Substantial And Durable Decreases In Serum APOC3 Restoring TG Homeostasis

**APOC3**

![Graph showing APOC3 levels over study weeks](image)

**Median (Q1,Q3)**

**Triglycerides**

![Graph showing triglycerides levels over study weeks](image)

**Study Week**

**Least Squares Mean**

**% Change from Baseline at Week 24**

- Placebo
- 10 mg Plozasiran
- 25 mg Plozasiran
- 50 mg Plozasiran

**Least Squares Mean**

**% Change from Baseline at Week 24**

- Placebo
- 10 mg Plozasiran
- 25 mg Plozasiran
- 50 mg Plozasiran

**SHASTA-2**: Data cutoff 14 Apr 2023; Analysis that removed n=2 participants with baseline values of BLOQ (ad hoc). *Statistical significance was determined using Mixed Model Repeat Measures (MMRM) analysis. APOC3, apolipoprotein C3; SEM, standard error of the mean; Q, quartile; TG, triglycerides.
Most Subjects Treated With Plozasiran Achieved Triglyceride Levels < 500 mg/dL, Below the Risk Threshold For Acute Pancreatitis

SHASTA-2: Data Cutoff 14 APR 2023. *Axis adjusted for one subject in Placebo group as outlier (percent change >400%).
N, number; TG, triglycerides; Wk, week.
**Plozasiran Decreases Remnant Cholesterol And Increases HDL-C**

**Remnant Cholesterol**

- Placebo
- 10 mg Plozasiran
- 25 mg Plozasiran
- 50 mg Plozasiran

**HDL-C**

- Placebo
- 10 mg Plozasiran
- 25 mg Plozasiran
- 50 mg Plozasiran

**LS Mean* % Change from Baseline at Week 24**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>% Change</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>-61%</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>10 mg</td>
<td>-63%</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>25 mg</td>
<td>-58%</td>
<td>p&lt;0.0001</td>
</tr>
</tbody>
</table>

**Shasta-2 Data Cutoff 14 Apr 2023:** *Based on calculation: Total cholesterol – HDL-C – LDL-C (ultracentrifugation) *Statistical significance was determined using Mixed Model Repeat Measures (MMRM) analysis. HDL-C: high density lipoprotein cholesterol; LS: least squares; SE, standard error; UC, ultracentrifuge
Plozasiran Impact On Additional Lipid Parameters

Non-HDL-C

LDL-C

Total ApoB

SHASTA-2: Data cutoff 14 Apr 2023. *Statistical significance was determined using Mixed Model Repeat Measures (MMRM) analysis. ApoB, apolipoprotein B; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; LS, least squares; SE, standard error.
# Summary Of Adverse Events

<table>
<thead>
<tr>
<th>TEAEs</th>
<th>Pooled Placebo (N=60)</th>
<th>Plozasiran 10 mg (N=54)</th>
<th>Plozasiran 25 mg (N=55)</th>
<th>Plozasiran 50 mg (N=57)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAEs</td>
<td>42 (70.0)</td>
<td>41 (75.9)</td>
<td>35 (63.6)</td>
<td>48 (84.2)</td>
</tr>
<tr>
<td>TEAEs occurring in ≥ 5 subjects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19</td>
<td>10 (16.7)</td>
<td>10 (18.5)</td>
<td>8 (14.5)</td>
<td>8 (14.0)</td>
</tr>
<tr>
<td>Worsening glycemic control*</td>
<td>7 (11.7)</td>
<td>12 (22.2)</td>
<td>9 (16.4)</td>
<td>11 (19.3)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (8.3)</td>
<td>3 (5.6)</td>
<td>1 (1.8)</td>
<td>1 (1.8)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>5 (8.3)</td>
<td>3 (5.6)</td>
<td>1 (1.8)</td>
<td>2 (3.5)</td>
</tr>
<tr>
<td>Headache</td>
<td>3 (5.0)</td>
<td>8 (14.8)</td>
<td>5 (9.1)</td>
<td>2 (3.5)</td>
</tr>
<tr>
<td>Treatment related adverse events</td>
<td>8 (13.3)</td>
<td>14 (25.9)</td>
<td>8 (14.5)</td>
<td>10 (17.5)</td>
</tr>
<tr>
<td>Serious TEAEs</td>
<td>7 (11.7)</td>
<td>4 (7.4)</td>
<td>2 (3.6)</td>
<td>5 (8.8)</td>
</tr>
<tr>
<td>TEAEs leading to drug discontinuation, dose interruptions, or study withdrawal</td>
<td>0</td>
<td>1 (1.9)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

TEAEs reported to date reflect the comorbidities and underlying conditions of the study population.

Serious TEAEs were not related to Plozasiran.

All serious TEAEs were resolved without sequelae (except 2 subjects with malignancies), with none with an outcome of death.

Data includes exposure out to 48 weeks.

SHASTA-2: Data cutoff 14 Apr 2023. *Worsening glycemic control defined by multiple glycemic control parameters including but not limited to hemoglobin A1c, new onset diabetes mellitus, type 2 diabetes mellitus, diabetes mellitus, hyperglycemia, insulin resistance. TEAEs, treatment emergent adverse events.
Plozasiran Reduces Triglycerides And Triglyceride Rich Lipoproteins in Subjects With SHTG

- Plozasiran durably decreases serum APOC3, TGs, and remnant cholesterol while increasing HDL-C at 24 weeks for all dose levels:
  - APOC3 reductions to -79%
  - TG reductions to -74%
  - Remnant cholesterol reductions to -63%
  - HDL-C increase up to +68%

- Over 90% of subjects treated with plozasiran achieved TG levels < 500 mg/dL, below the risk threshold for Acute Pancreatitis

- Plozasiran has a favorable safety profile to date

- These data support further development of plozasiran in planned phase 3 programs for the treatment of FCS and SHTG

- Based on these results, RNAi-mediated silencing of hepatic APOC3 expression via plozasiran is a promising potential treatment for subjects with SHTG
THANK YOU
WE WOULD LIKE TO THANK THE PATIENTS AND CAREGIVERS WHO PARTICIPATED IN THIS STUDY